Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | UBE2N | P61088 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | HEXA | P06865 | 2/20 | 0.50 |
| ▸ | HEXB | P07686 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2959641 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APKMCYP1B1 | |
| SCHEMBL30711693 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MEN1KMT2APKMCYP1B1 | |
| SCHEMBL4100027 | 0.85 | HSD17B10 (0.78) | ALDH1A1MEN1KMT2APKMCYP1B1 | |
| SCHEMBL19889218 | 0.77 | MEN1 (0.68) | ALDH1A1MEN1KMT2APKMCYP1B1 | |
| SCHEMBL4095113 | 0.77 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2APKMCYP1B1 | |
| SCHEMBL8377843 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MEN1KMT2APKMCYP1B1 | |
| SCHEMBL8314773 | 0.76 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2APKMCYP1B1 | |
| SCHEMBL5594225 | 0.76 | NPSR1 (1.00) | ALDH1A1MEN1KMT2ACYP1B1NPSR1 | |
| SCHEMBL4625520 | 0.74 | ALDH1A1 (0.69) | ALDH1A1MEN1KMT2APKMCYP1B1 | |
| SCHEMBL28765224 | 0.73 | MEN1 (0.62) | ALDH1A1MEN1KMT2APKMCYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | claimed |
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | claimed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | claimed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | claimed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | claimed |
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20080287484-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2008-11-20 | — | — | US | disclosed |
| US-7291629-B2 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-11-06 | — | — | US | disclosed |
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | disclosed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | disclosed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | disclosed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215815-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | ALDH1A1 1561/4885MEN1 4269/4885KMT2A 3457/4885 |
| US-20050250807-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | ALDH1A1 1739/4885MEN1 4175/4885KMT2A 3637/4885 |
| US-20020169182-A1 | Neurotrophin antagonist compositions | NTRK2, NGF, BDNF | ALDH1A1 1523/4885MEN1 4752/4885KMT2A 3113/4885 |
| US-20080287484-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | ALDH1A1 1866/4885MEN1 4146/4885KMT2A 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.